T1	intervention 52 71	Omega-3 Fatty Acids
T2	duration 546 552	2-year
T3	No-of-participants 594 597	266
T4	eligibility 598 709	healthy postmenopausal women (50% normal weight, 30% overweight, 20% obese) with high breast density (BD; â‰¥25%)
T5	control 829 850	no treatment, control
T6	intervention 857 867	raloxifene
T7	intervention 910 916	lovaza
T8	outcome-Measure 975 987	change in BD
T9	outcome 1294 1316	increase in plasma DHA
T10	outcome 1339 1374	decrease in absolute breast density
